How the evolution of multicellularity set the stage for cancer

[1]  M. Campone,et al.  Comment on ‘How the evolution of multicellularity set the stage for cancer’ , 2018, British Journal of Cancer.

[2]  R. Pearson,et al.  Altered interactions between unicellular and multicellular genes drive hallmarks of transformation in a diverse range of solid tumors , 2017, Proceedings of the National Academy of Sciences.

[3]  K. Bussey,et al.  Ancient genes establish stress-induced mutation as a hallmark of cancer , 2017, PloS one.

[4]  L. Abrahmsén,et al.  Inhibiting the system xC−/glutathione axis selectively targets cancers with mutant-p53 accumulation , 2017, Nature Communications.

[5]  C. Arenas-Mena.  The origins of developmental gene regulation , 2017, Evolution & development.

[6]  P. Aloy,et al.  Quantification of Pathway Cross-talk Reveals Novel Synergistic Drug Combinations for Breast Cancer. , 2017, Cancer research.

[7]  H. Azevedo,et al.  Topological robustness analysis of protein interaction networks reveals key targets for overcoming chemotherapy resistance in glioma , 2015, Scientific Reports.

[8]  J. Sturm,et al.  Ancient hot and cold genes and chemotherapy resistance emergence , 2015, Proceedings of the National Academy of Sciences.

[9]  M. Hochberg,et al.  Cancer across the tree of life: cooperation and cheating in multicellularity , 2015, Philosophical Transactions of the Royal Society B: Biological Sciences.

[10]  Xionglei He,et al.  The reverse evolution from multicellularity to unicellularity during carcinogenesis , 2015, Nature Communications.

[11]  N. Sonenberg,et al.  Targeting the translation machinery in cancer , 2015, Nature Reviews Drug Discovery.

[12]  E. Dermitzakis,et al.  Gene age predicts the strength of purifying selection acting on gene expression variation in humans. , 2014, American journal of human genetics.

[13]  Hsuan-Cheng Huang,et al.  Dissecting the Human Protein-Protein Interaction Network via Phylogenetic Decomposition , 2014, Scientific Reports.

[14]  B. Weaver,et al.  How Taxol/paclitaxel kills cancer cells , 2014, Molecular biology of the cell.

[15]  C. Lineweaver,et al.  Targeting cancer's weaknesses (not its strengths): Therapeutic strategies suggested by the atavistic model , 2014, BioEssays : news and reviews in molecular, cellular and developmental biology.

[16]  K. Wiman,et al.  Mutant p53 reactivation by small molecules makes its way to the clinic , 2014, FEBS letters.

[17]  Kwang-Hyun Cho,et al.  Robustness and Evolvability of the Human Signaling Network , 2014, PLoS Comput. Biol..

[18]  Jason Li,et al.  Response of BRAF-mutant melanoma to BRAF inhibition is mediated by a network of transcriptional regulators of glycolysis. , 2014, Cancer discovery.

[19]  Robert A. Gatenby,et al.  Life history trade-offs in cancer evolution , 2013, Nature Reviews Cancer.

[20]  Jing Yang,et al.  Epithelial–mesenchymal plasticity in carcinoma metastasis , 2013, Genes & development.

[21]  R. Pearson,et al.  Targeting RNA polymerase I transcription and the nucleolus for cancer therapy , 2013, Expert opinion on therapeutic targets.

[22]  James U. Bowie,et al.  Network rewiring is an important mechanism of gene essentiality change , 2012, Scientific Reports.

[23]  Y. Pilpel,et al.  Chromosomal duplication is a transient evolutionary solution to stress , 2012, Proceedings of the National Academy of Sciences.

[24]  Carleen Cullinane,et al.  Inhibition of RNA polymerase I as a therapeutic strategy to promote cancer-specific activation of p53. , 2012, Cancer cell.

[25]  J. Ricci,et al.  Glycolysis inhibition targets Mcl-1 to restore sensitivity of lymphoma cells to ABT-737-induced apoptosis , 2012, Leukemia.

[26]  R. Perez-soler,et al.  Bortezomib: Understanding the Mechanism of Action , 2011, Molecular Cancer Therapeutics.

[27]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[28]  C. Lineweaver,et al.  Cancer tumors as Metazoa 1.0: tapping genes of ancient ancestors , 2011, Physical biology.

[29]  Hyunsuk Shim,et al.  Metabolic positron emission tomography imaging in cancer detection and therapy response. , 2011, Seminars in oncology.

[30]  Gary D. Bader,et al.  Pathway Commons, a web resource for biological pathway data , 2010, Nucleic Acids Res..

[31]  A. Levine,et al.  The origins and evolution of the p53 family of genes. , 2010, Cold Spring Harbor perspectives in biology.

[32]  Diethard Tautz,et al.  Phylostratigraphic tracking of cancer genes suggests a link to the emergence of multicellularity in metazoa , 2010, BMC Biology.

[33]  S. Kauffman,et al.  Cancer attractors: a systems view of tumors from a gene network dynamics and developmental perspective. , 2009, Seminars in cell & developmental biology.

[34]  L. Cantley,et al.  Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation , 2009, Science.

[35]  Vasilis Vasiliou,et al.  Human ATP-binding cassette (ABC) transporter family , 2009, Human Genomics.

[36]  R. Russell,et al.  Targeting and tinkering with interaction networks. , 2008, Nature chemical biology.

[37]  Hiroaki Kitano,et al.  Biological robustness , 2008, Nature Reviews Genetics.

[38]  Mel Greaves,et al.  Darwinian medicine: a case for cancer , 2007, Nature Reviews Cancer.

[39]  Paul A. Bates,et al.  Global topological features of cancer proteins in the human interactome , 2006, Bioinform..

[40]  Miklos Pless,et al.  Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  N. Sonenberg,et al.  eIF4E – from translation to transformation , 2004, Oncogene.

[42]  M. Jordan,et al.  Microtubules as a target for anticancer drugs , 2004, Nature Reviews Cancer.

[43]  C. Stoeckert,et al.  OrthoMCL: identification of ortholog groups for eukaryotic genomes. , 2003, Genome research.

[44]  Bart Barlogie,et al.  A phase 2 study of bortezomib in relapsed, refractory myeloma. , 2003, The New England journal of medicine.

[45]  A. Barabasi,et al.  Hierarchical Organization of Modularity in Metabolic Networks , 2002, Science.

[46]  John Doyle,et al.  Complexity and robustness , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[47]  P. D'Arpa,et al.  Mechanism of Action of Camptothecin , 1996, Annals of the New York Academy of Sciences.

[48]  L. Sachs.  Control of normal cell differentiation and the phenotypic reversion of malignancy in myeloid leukaemia , 1978, Nature.

[49]  Xionglei He,et al.  The Convergent Cancer Evolution toward a Single Cellular Destination. , 2016, Molecular biology and evolution.

[50]  R. Pearson,et al.  Combination Therapy Targeting Ribosome Biogenesis and mRNA Translation Synergistically Extends Survival in MYC-Driven Lymphoma. , 2016, Cancer discovery.

[51]  Ellen Clarke.  Evolutionary Transitions to Multicellular Life , 2016 .

[52]  R. Solé,et al.  Evolutionary Transitions to Multicellular Life: Principles and mechanisms , 2015 .

[53]  M. Vincent.  Cancer: a de-repression of a default survival program common to all cells?: a life-history perspective on the nature of cancer. , 2012, BioEssays : news and reviews in molecular, cellular and developmental biology.

[54]  A. Barabasi,et al.  Network medicine : a network-based approach to human disease , 2010 .